These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Fomivirsen.
    Author: Highleyman L.
    Journal: BETA; 1998 Apr; ():29, 31. PubMed ID: 11365261.
    Abstract:
    Clinical trials indicate that Isis Pharmaceuticals' Fomivirsen (ISIS 2922) is a promising treatment for cytomegalovirus (CMV) retinitis. CMV, a progressive and chronic condition, affects up to 40 percent of people with AIDS, and can lead to blindness. Phase I and Phase II trials showed that the drug halted CMV progression and prolonged remission in patients with both early and advanced disease. The first reports from a Phase III trial were reported at the 5th Conference on Retroviruses and Opportunistic Infections. The drug appears safe in trials, and no patient left the trials due to side effects. Side effects included minor vision defects, increased pressure within the eye, and eye inflammation that responded readily to topical corticosteroid drops. Fomivirsen is based on antisense technology, a type of gene therapy. Its antiviral actions and other current CMV treatments are described.
    [Abstract] [Full Text] [Related] [New Search]